Join Growin Stock Community!

生華科6492.TW Overview

TW StockBiotech. & Medical
(No presentation for 6492)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

生華科（6492）Overall Performance

生華科（6492）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

生華科（6492） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

生華科（6492）Key Information

生華科（6492）Profile

Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidnarulex and talazoparib in patients with metastatic castration resistant prostate cancer. It is also developing CX-4945-CCA that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-4945-BCC, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and CX-4945-MB, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma. In addition, the company develops CX-4945-AV06, a phase II, double blind randomized, controlled study to evaluate the safety and efficacy of CX-4945 in hospitalized adults with COVID-19. Senhwa Biosciences, Inc. was incorporated in 2012 and is based in New Taipei City, Taiwan.

生華科（6492）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
49.35%
Net Margin
-24440.83%
Revenue Growth (YoY)
8.00%
Profit Growth (YoY)
4.10%
3-Year Revenue Growth
9.70%
3-Year Profit Growth
-5.18%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
49.35%
Net Margin
-24440.83%
Revenue Growth (YoY)
8.00%
Profit Growth (YoY)
4.10%
3-Year Revenue Growth
9.70%
3-Year Profit Growth
-5.18%
default symbol

6492

生華科

49.70D

-1.81%

(-0.02)

  • When is 6492's latest earnings report released?

    The most recent financial report for 生華科 (6492) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6492's short-term business performance and financial health. For the latest updates on 6492's earnings releases, visit this page regularly.

  • What is the operating profit of 6492?

    According to the latest financial report, 生華科 (6492) reported an Operating Profit of -70.22M with an Operating Margin of -21,279.39% this period, representing a growth of 16.24% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6492's revenue growth?

    In the latest financial report, 生華科 (6492) announced revenue of 330K, with a Year-Over-Year growth rate of 32%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6492 have?

    At the end of the period, 生華科 (6492) held Total Cash and Cash Equivalents of 825.71M, accounting for 0.94 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6492 go with three margins increasing?

    In the latest report, 生華科 (6492) did not achieve the “three margins increasing” benchmark, with a gross margin of 40.3%%, operating margin of -21,279.39%%, and net margin of -20,099.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6492's profit trajectory and future growth potential.

  • Is 6492's EPS continuing to grow?

    According to the past four quarterly reports, 生華科 (6492)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.74. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6492?

    生華科 (6492)'s Free Cash Flow (FCF) for the period is 813K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 68.43% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.